Efficacy and safety of mesalazine (Salofalk®) in an open study of 20 patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 30, Issue 7, 2003, Pages 1558-1560

  Van Denderen, J Christiaan ^b   Van der Horst Bruinsma, Irene E ^a   Bezemer, P Dick ^b   Dijkmans, Ben A C ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Ankylosing spondylitis; Mesalazine

Indexed keywords

C REACTIVE PROTEIN; LIVER ENZYME; MESALAZINE;

ABDOMINAL PAIN; ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECZEMA; ENTHESOPATHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMPOTENCE; LABORATORY DIAGNOSIS; MALE; MORNING STIFFNESS; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; STATISTICAL SIGNIFICANCE; SYNOVITIS; VERTIGO; VISUAL ANALOG SCALE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD SEDIMENTATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; JOINTS; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 0037490977     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ 1986;293:911-4.
2. Feltelius N, Hallgren R. Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 1986;45:396-9.
3. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis; a twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-6.
4. Corkill MM, Jobanputra P, Gibson T, Macfarlane DG. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Br J Rheumatol 1990;29:41-5.
5. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991;10:43-8.
6. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729-33.
7. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy; a randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995:38:618-27.
8. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis; a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2004-12.
9. Dekker-Saeys BJ, Dijkmans BAC, Tytgat GNJ. Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol 2000;27:723-6.
10. Thomson GTD, Thomson BRJ, Siwik Thomson K, Santos Ducharme J. Clinical efficacy of mesalazine in the treatment of the spondyloarthropathies. J Rheumatol 2000;27:714-8.
11. Taggart A, Gardiner P, McEvoy F, Hopkins R, Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis? Arthritis Rheum 1996;39:1400-5.
12. Jones SD, Porter J, Garret SL, Kennedy LG, Whitelock H, Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) [letter]. J Rheumatol 1995;22:1609.
13. Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N, on behalf of the ASAS Working Group. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1999;26:951-4.
14. Mielants H, Veys EM, Cuvelier C, de Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation; II. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985;12:294-8.